CCORF Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Optimistic Outlook for Oncolytics Biotech With Continued Buy Rating Amidst Promising Trial Results
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), R1 RCM (RCM) and Lumos Pharma (LUMO)
Oncolytics Biotech (ONCY) Receives a Buy From RBC Capital
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Oncolytics Biotech (ONCY) and Irhythm Technologies (IRTC)
Maxim Group Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
CCORF Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Buy Rating on Oncolytics Biotech Backed by Strong Clinical Trials and Strategic Partnerships
Oncolytics Biotech Analyst Ratings
Buy Rating Affirmed on Oncolytics Biotech's Advancements and Prospective Partnerships in Cancer Treatment Pipeline
Analysts' Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Aveanna Healthcare Holdings (AVAH) and Sanofi (OtherSNYNF)
Analysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)
Oncolytics Biotech Analyst Ratings
Buy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trials
Buy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trials
Oncolytics Biotech Analyst Ratings
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Maintains $5 Price Target
Oncolytics Biotech (ONCY) Gets a Buy From RBC Capital
Oncolytics Biotech Analyst Ratings
Reiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech's Pipeline